Head and Neck-Journal for the Sciences and Specialties of the Head and Neck最新文献

{"title":"Socioeconomic Disparities in Head Neck Cancer Incidence and Mortality: Regional Wealth-Dependent Analysis in Seniors Cohorts.","authors":"Małgorzata Wierzbicka, Dorota Świątek, Jakub Sikora, Wirginia Likus, Wioletta Pietruszewska, Jarosław Markowski","doi":"10.1002/hed.28156","DOIUrl":"https://doi.org/10.1002/hed.28156","url":null,"abstract":"<p><strong>Background: </strong>Head and neck cancer (HNC) shows a \"diverging scissors\" pattern, with incidence and mortality linked to regional economic status.</p><p><strong>Objective: </strong>We aim to investigate whether socioeconomic disparities between regions correlate with widening gaps in HNC incidence and mortality rates, with particular emphasis on age-related patterns among elderly populations.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Setting: </strong>Data from the National Cancer Registry for females from 2003 to 2019.</p><p><strong>Patients: </strong>76 649 patients, 49 858 males, 26 791 females from 2003 to 2019 in age cohorts: 60-69, 70-79, and 80+, covering all voivodeships in Poland.</p><p><strong>Measurements: </strong>Five Groups were established based on the Wealth Indicator (WI) value, from 54,72 to 243,66 EUR in G1-G5, respectively. Trend lines for incidence and mortality rates were calculated, and slope tests were used to determine statistical significance: positive incidence rate (IR)(+), mortality rate (MR)(+), neutral (IR(0), MR(0)), or negative (IR(-), MR(-)). Comparative analyses included slope differences between incidence and mortality trends (IR>MR, IR=MR, IR<MR) using tests with Bonferroni correction.</p><p><strong>Results: </strong>HNC incidence and mortality rates have risen consistently over two decades, regardless of regional economic status. More affluent regions show a better incidence-to-mortality ratio, but no improvement is seen in the 80+ age group. Female patients achieve consistently better outcomes than males across all regions and age groups.</p><p><strong>Limitations: </strong>Despite the optimal selection of the WI (Wealth Indicator) indicator, it does not fully reflect the income stratification issue, particularly in the G5, the wealthiest group. The analysis does not capture the problem of increased incidence rates in the most industrialized region.</p><p><strong>Conclusion: </strong>The findings highlight the need for enhanced screening protocols for males to address gender disparities in HNC outcomes and tailored therapeutic strategies for the 80+ age group.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic Resonance Imaging and [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Guided Therapy Improves Survival in Upper Aerodigestive Tract NK/T-Cell Lymphoma, Nasal Type: A Prospective Cohort Study.","authors":"Quanguang Ren, Yue Cui, He Huang, Xueying Li, Huangming Hong, Zhao Wang, Xiaojie Fang, Chengcheng Guo, Yuyi Yao, Zegeng Chen, Ying Huang, Zhiming Li, Qingqing Cai, Ying Tian, Hanyu Wang, Xiaoping Lin, Wei Fan, Lie Zheng, Suxia Lin, Ying Guo, Tongyu Lin","doi":"10.1002/hed.28137","DOIUrl":"https://doi.org/10.1002/hed.28137","url":null,"abstract":"<p><strong>Background: </strong>To investigate the value of pretreatment nasopharyngeal and neck magnetic resonance imaging (NN-MRI) combined with positron emission tomography (PET)/CT-guided therapy for improving survival in upper aerodigestive tract NK/T-cell lymphoma (UADT-NKTL) patients.</p><p><strong>Methods: </strong>We performed a prospective cohort study including 171 untreated patients histologically diagnosed with UADT-NKTL, of whom 71 patients received PET/CT combined with NN-MRI and the other 100 patients received PET/CT alone. The clinical stage of every patient was classified according to the Ann Arbor and TNM staging systems. Clinical stage, target volume delineation, and survival were evaluated and compared for PET/CT with and without NN-MRI.</p><p><strong>Results: </strong>By detecting additional local lesions, NN-MRI upgraded the clinical stages on the basis of the Ann Arbor staging system and TNM staging system compared to the results of PET/CT (9/71, p = 0.011; 11/71, p = 0.019, respectively), which revised the target volume delineation of radiotherapy (9/71) in the PET/CT-MRI group. Compared with those in the PET/CT group, 3-year local recurrence-free survival was prolonged in the PET/CT-MRI group (100% vs. 74.9%; p < 0.001), and 3-year overall survival and progression-free survival were better in the PET/CT-MRI group (84.5% vs. 76.3%, p = 0.04 and 78.3% vs. 67.3%, p = 0.03, respectively).</p><p><strong>Conclusion: </strong>NN-MRI and PET/CT-guided therapy could complementarily assist in optimizing the determination of clinical stage and target delineation, which could improve the prognosis of UADT-NKTL patients.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-Hypofractionated Radiotherapy for Early-Stage Glottic Cancer: Real-World Data From a Single Center.","authors":"Mete Gundog, Esin Kiraz","doi":"10.1002/hed.28139","DOIUrl":"https://doi.org/10.1002/hed.28139","url":null,"abstract":"<p><strong>Background: </strong>In recent years, smaller-volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra-hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients.</p><p><strong>Methods: </strong>This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35-42.5 Gy in 5 fractions.</p><p><strong>Results: </strong>On a 59-month median follow-up, the 5-year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5-year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV_D98 (> 41.08 Gy) was found to be statistically significant in surgery-needed events (HR: 22.4, 95% CI: 1.9-252.1, p = 0.01).</p><p><strong>Conclusion: </strong>Single-cord ultra-hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early and Long-Term Thyroid Dysfunction in Patients With Head and Neck Squamous Cell Carcinoma After External Radiotherapy: Clinicopathological Risk Factors.","authors":"Adriana Russo Fiore, Gustavo Jacob Lourenço, Eduardo Baldon Pereira, Luciana Freire De Almeida Dos Anjos, Carmen Silvia Passos Lima, Denise Engelbrecht Zantut-Wittmann","doi":"10.1002/hed.28150","DOIUrl":"https://doi.org/10.1002/hed.28150","url":null,"abstract":"<p><strong>Background: </strong>To evaluate thyroid dysfunction(TD) among patients with head and neck squamous cell carcinoma (HNSCC) submitted to external radiotherapy (RT).</p><p><strong>Methods: </strong>The study focused on early and long-term TD in 285 HNSCC patients treated with RT alone or combined with radiochemotherapy and/or surgery.</p><p><strong>Results: </strong>A total of 156 (54.7%) patients presented TD during follow-up, 153 (53.7%) TD in long-term. Subclinical hypothyroidism (SCH) was the TD first identified in 43.5%; persisted in 68.5%, evolved to overt hypothyroidism in 21%, central hypothyroidism in 0.8%, returned to euthyroidism in 9.7%. TD first detection was 7.2 months after RT, 3.85 months for subclinical thyrotoxicosis, 17.77 months for SCH. Type 2 diabetes mellitus (DM2), metastatic lymph nodes, no tumor resection were TD risk factors. All patients with TSH ≥ 7.5 mIU/mL developed primary/SCH, 19.5% with TSH < 7.5 mIU/mL remained euthyroid at long-term follow-up.</p><p><strong>Conclusion: </strong>Frequent monitoring of thyroid function is necessary in patients with HNSCC after RT, particularly with DM2, lymph node involvement, no surgical tumor resection.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.","authors":"Aarti Bhatia, Ranee Mehra, Jessica Bauman, Saad A Khan, Wei Wei, Veronique Neumeister, Teresa Sandoval-Schaefer, R Katherine Alpaugh, Miriam Lango, David L Rimm, John A Ridge, Barbara Burtness","doi":"10.1002/hed.28152","DOIUrl":"https://doi.org/10.1002/hed.28152","url":null,"abstract":"<p><p>Prognosis for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC) remains poor. We hypothesized that the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to standard therapy would improve responses by inhibiting nuclear translocation of EGFR and designed a phase 2 trial of chemotherapy, cetuximab, and erlotinib in patients with R/M HNSCC. A 24 patients were enrolled and treated with carboplatin, paclitaxel, and cetuximab administered in 21-day cycles. Erlotinib was added with cycle 2. The primary end point was the objective response rate (ORR). The secondary end points were toxicity, overall survival (OS) and laboratory correlates. Median age was 65.5 years. Median duration on treatment was 4.6 months. ORR with cycle 1 of treatment was 33.3%, and for cycle 2 and beyond was 58.3%. Median progression-free survival (PFS) was 6.2 months, and median OS was 10.6 months. Most common treatment-related adverse events included anemia, neutropenia, skin rash, diarrhea, and hypomagnesemia. Dual EGFR blockade was tolerable and efficacious in this small patient sample. With an ORR of 58.3%, the study met its primary endpoint. PFS and OS were comparable to historical controls. Dual EGFR targeting without the chemotherapy backbone is worthy of further study. Trail Registration: ClinicalTrials.gov identifier: NCT01316757.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review.","authors":"Brian A Keith, Evan S Chernov, Shaun A Nguyen, Jyotika K Fernandes, William G Albergotti","doi":"10.1002/hed.28155","DOIUrl":"https://doi.org/10.1002/hed.28155","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of adjuvant radioactive iodine (RAI) therapy in intermediate- and high-risk differentiated thyroid carcinoma (DTC) remains unclear, particularly for papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).</p><p><strong>Methods: </strong>This scoping review, following PRISMA-ScR guidelines, analyzed studies from PubMed, Scopus, and CINAHL through July 14, 2023. Data on demographics, cancer characteristics, treatment details, and clinical outcomes were extracted. A limited meta-analysis of continuous measures, proportions, and hazard ratios was performed.</p><p><strong>Results: </strong>Nineteen studies were included, revealing significant variability across studies. Meta-analysis was limited to overall survival (OS) in intermediate-risk PTC due to methodological heterogeneity across studies. Kaplan-Meier survival curves were inconsistent, RAI activity was often unreported, and complications of RAI were rarely addressed.</p><p><strong>Conclusions: </strong>Methodological heterogeneity hinders the assessment of adjuvant RAI efficacy between histological variants. Further randomized trials with extended follow-up and improved reporting are needed to better compare the effects of adjuvant RAI in PTC and FTC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Intensity Modulated Proton Therapy for Salivary Gland Carcinoma: High Local Control and Quality of Life Preservation.","authors":"Gaku Takano, Daisuke Kawakita, Hiromitsu Iwata, Yukiko Hattori, Koichiro Nakajima, Yusuke Tsuzuki, Shuou Sudo, Toshiyuki Toshito, Kensuke Hayashi, Takuma Matoba, Michi Sawabe, Kiyoshi Minohara, Sho Iwaki, Kazuyuki Nakai, Yu Iwase, Shinichi Iwasaki, Hiroyuki Ogino","doi":"10.1002/hed.28149","DOIUrl":"https://doi.org/10.1002/hed.28149","url":null,"abstract":"<p><strong>Background: </strong>In recent years, particle therapy has shown promise as a local treatment for salivary gland carcinoma (SGC); however, its efficacy and safety remain unclear. This study aimed to evaluate the clinical outcomes of intensity-modulated proton therapy (IMPT) for SGC.</p><p><strong>Methods: </strong>We performed a single-institution retrospective analysis of patients with SGC who underwent IMPT.</p><p><strong>Results: </strong>IMPT was performed on 28 SGC patients, of which 18 were for definitive treatment and 10 were for postoperative treatment. The 2-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates for definitive treatment cases were 70.1%, 25.0%, and 82.5%, respectively. The 2-year OS, PFS, and LC rates for postoperative treatment cases were 100%, 80.0%, and 90.0%, respectively. Quality of life scores in the EORTC QLQ-C30 and QLQ-HN35 were preserved for 1 year after treatment.</p><p><strong>Conclusions: </strong>Our study suggests the efficacy and safety of IMPT in SGC patients.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Pain, Anxiety, and Depressive Symptoms With Sleep Outcomes in Patients With Head and Neck Squamous Cell Carcinoma: A Cross-Sectional Observational Study.","authors":"Giseli Mitsuy Kayahara, Bruna Amélia Moreira Sarafim-Costa, Marcus Vinícius Branco de Oliveira, Antônio Mendes Fontanelli, Yi Ye, Vitor Bonetti Valente, Eder Ricardo Biasoli, Glauco Issamu Miyahara, Daniel Galera Bernabé","doi":"10.1002/hed.28147","DOIUrl":"https://doi.org/10.1002/hed.28147","url":null,"abstract":"<p><strong>Background: </strong>This exploratory cross-sectional observational study sought to characterize sleep quality and evaluate its association with sociodemographic, clinicopathological, behavioral, and psychological variables in patients with head and neck squamous cell carcinoma (HNSCC).</p><p><strong>Patients and methods: </strong>Sleep problems from 132 HNC patients were assessed before starting oncological treatment through the questionnaires Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and STOP-Bang. Anxiety and depression symptoms were evaluated using the Hospital Anxiety and Depression Scale. Univariate analysis and multivariate logistic regression were performed to evaluate factors associated with sleep problems in HNSCC patients.</p><p><strong>Results: </strong>About 50% of the HNSCC patients reported poor overall sleep quality on the PSQI. Insomnia, excessive daytime sleepiness, and high risk of apnea were observed in 19%, 15%, and 54% of HNSCC patients, respectively. Our results showed that pain was associated with overall poor PSQI sleep quality and lower PSQI sleep efficiency, while the presence of regional metastasis was linked to overall PSQI good sleep. No other clinicopathological or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Higher occurrence of anxiety symptoms was related to poor overall PSQI sleep quality, decreased PSQI sleep efficiency, PSQI daytime dysfunction, and ISI insomnia. Moreover, higher occurrence of depression symptoms was associated with lower PSQI sleep latency and PSQI duration, and the occurrence of ESS excessive daytime sleepiness.</p><p><strong>Conclusion: </strong>Pain, anxiety, and depressive symptoms were associated with poor sleep quality and sleep problems in HNSCC patients before starting treatment. No sociodemographic or behavioral (i.e., alcohol and tobacco use) variables were related to sleep outcomes. Likewise, tumor location, T classification, and clinical staging were not linked to sleep quality and disorders in HNSCC patients.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Stratification for Extranodal Extension in Head and Neck Cancers-Implication for Treatment Intensification.","authors":"Smriti Panda, Rajeev Kumar, Aanchal Kakkar, Sandipta Mitra, Vishwajeet Singh, Alok Thakar, Chirom Amit Singh, Kapil Sikka, Anup Singh, Kavneet Kaur, Aman Sharma, Akash Kumar, Amit Kumar, Rachit Sood, Karthika Chettuvatti, Areej Moideen, Nongthombam Surjalata Devi","doi":"10.1002/hed.28144","DOIUrl":"https://doi.org/10.1002/hed.28144","url":null,"abstract":"<p><strong>Background: </strong>Extranodal extension (ENE) is an important adverse prognostic indicator for head and neck cancers. However, ENE needs further risk stratification in terms of optimum cutoff for the extent of ENE and interaction with clinicopathological risk factors.</p><p><strong>Methods: </strong>Retrospective single-center study on patients with treatment-naïve head and neck cancer with final histology indicating ENE.</p><p><strong>Results: </strong>Pathological ENE was observed in 122 patients (12.4%). With the 2 mm cutoff separating Mi-ENE and Ma-ENE, no difference was observed in overall survival (OS) and disease-free survival (DFS) for unmatched (OS: 40.9% vs. 33.6%, p = 0.7; DFS: 34.05% vs. 26.12%, p = 0.5) as well as propensity score-matched cohort (OS: HR 1.08, p = 0.82; DFS: HR 0.95, p = 0.89). Receiver-operator curve (ROC) analysis showed the highest area under the curve with a 4 mm cutoff for the extent of ENE (AUC: 0.52). On assessing the impact of adjuvant chemoradiation (CRT) on Ma-ENE and Mi-ENE, only Ma-ENE showed OS (HR: 0.42, 95% CI: 0.18-0.9) and DFS (HR: 0.33, 95% CI: 0.15-0.70) benefit with CRT, which was statistically significant. The revised 4 mm cutoff was predictive of therapeutic benefit with adjuvant CRT (HR: 0.27, 95% CI: 0.1-0.73). Clinicopathological factors with statistically significant interaction with ENE in worsening OS and DFS were tumor location in tongue/floor of mouth (OS), T3/T4 category (OS), depth of invasion greater than 10 mm (OS), ≥ 5 nodes with metastasis (OS), and male sex (DFS).</p><p><strong>Conclusion: </strong>The standard 2 mm cutoff for the extent of ENE failed to reveal sufficient hazard discrimination for OS/DFS. Instead, the 4 mm cutoff determined on ROC analysis was found to have the best predictive ability for DFS.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.","authors":"Ryosuke Sato, Takahiro Inoue, Risa Wakisaka, Hiroki Komatsuda, Michihisa Kono, Hidekiyo Yamaki, Kenzo Ohara, Takumi Kumai, Akemi Kosaka, Takayuki Ohkuri, Toshihiro Nagato, Kan Kishibe, Hiroya Kobayashi, Miki Takahara","doi":"10.1002/hed.28151","DOIUrl":"https://doi.org/10.1002/hed.28151","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of anti-PD-1 and EGFR therapies for head and neck squamous cell carcinoma (HNSCC) can be predicted using various markers; however, the stability of these markers remains unclear.</p><p><strong>Methods: </strong>In this retrospective study, laboratory findings and tissue expression of PD-L1, PD-L2, and EGFR were analyzed in 79 paired naive and recurrent HNSCC tumors. Laboratory findings were also analyzed in nonrecurrent patients using a propensity score-matched analysis. PD-L1 and PD-L2 expression levels were assessed using tumor proportion score (TPS) and combined positive score (CPS), whereas EGFR was evaluated using the H-score.</p><p><strong>Results: </strong>White blood cell, neutrophil, lymphocyte, and monocyte counts and lymphocyte-monocyte ratios were significantly lower in the patients after the first-line treatment regardless of recurrence. PD-L1, PD-L2, and EGFR expression changed in 30%-40% of tumor pairs. Immune but not tumoral PD-L1 positivity rates were significantly higher in the patients with early recurrence.</p><p><strong>Conclusions: </strong>The expression of immune checkpoints including PD-L1 in naive tumors does not reflect those in recurrent tumors. Increasing PD-L1 expression in immune cells may cause early recurrence of HNSCC.</p>","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}